Shaygan Nejad V - Search Results

1

Evaluation of the Prevalence of Anti-transglutaminase 2 and 6 Antibodies in Patients with Sero-Positive Multiple Sclerosis.

Emami MH, Najafi MR, Allahdadian S, Mohammadzadeh S, Jamali N, Lalazarian A, Shaygan Nejad V, Maghool F. Emami MH, et al. Among authors: shaygan nejad v. Middle East J Dig Dis. 2024 Jan;16(1):47-51. doi: 10.34172/mejdd.2024.368. Epub 2024 Jan 31. Middle East J Dig Dis. 2024. PMID: 39050097 Free PMC article.

2

The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines.

Zandifar A, Masjedi SS, Haghdoost F, Asgari F, Manouchehri N, Banihashemi M, Najafi MR, Ghorbani A, Zolfaghari B, Gholamrezaei A, Shaygannejad V, Saadatnia M. Zandifar A, et al. ScientificWorldJournal. 2013 Aug 27;2013:950245. doi: 10.1155/2013/950245. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24068887 Free PMC article.

3

Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran.

Salari M, Mirmosayyeb O, Etemadifar M, Shaygannejad V, Khorvash F, Najafi MR, Ashtari F, Chitsaz A. Salari M, et al. Iran J Neurol. 2018 Jan 5;17(1):6-10. Iran J Neurol. 2018. PMID: 30186553 Free PMC article.

4

Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis.

Barzegar M, Allahdadian S, Mirmosayyeb O, Azarbayejani R, Badihian S, Nehzat N, Daryanavardi S, Barzegar S, Shaygannejad V. Barzegar M, et al. Psychol Health Med. 2022 Jul;27(6):1234-1244. doi: 10.1080/13548506.2020.1859564. Epub 2020 Dec 10. Psychol Health Med. 2022. PMID: 33300373

5

Prevalence of multiple sclerosis in Isfahan, Iran.

Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Etemadifar M, et al. Neuroepidemiology. 2006;27(1):39-44. doi: 10.1159/000094235. Epub 2006 Jun 27. Neuroepidemiology. 2006. PMID: 16804333

6

Effects of rivastigmine on memory and cognition in multiple sclerosis.

Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Shaygannejad V, et al. Can J Neurol Sci. 2008 Sep;35(4):476-81. doi: 10.1017/s0317167100009148. Can J Neurol Sci. 2008. PMID: 18973065 Clinical Trial.

7

Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?

Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A. Ashtari F, et al. Neurol Neurochir Pol. 2009 Sep-Oct;43(5):428-32. Neurol Neurochir Pol. 2009. PMID: 20054744 Clinical Trial.

8

Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.

Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Maghzi AH, Fatehi F. Basiri K, et al. Acta Med Iran. 2012;50(2):97-100. Acta Med Iran. 2012. PMID: 22359077 Free article.

9

Color blindness among multiple sclerosis patients in Isfahan.

Shaygannejad V, Golabchi K, Dehghani A, Ashtari F, Haghighi S, Mirzendehdel M, Ghasemi M. Shaygannejad V, et al. J Res Med Sci. 2012 Mar;17(3):254-7. J Res Med Sci. 2012. PMID: 23267377 Free PMC article.

10

What is the Real Fate of Vitamin D in Multiple Sclerosis?

Shaygannejad V, Tolou-Ghamari Z. Shaygannejad V, et al. Int J Prev Med. 2013 May;4(Suppl 2):S159-64. Int J Prev Med. 2013. PMID: 23776718 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters